【病毒外文文獻】1990 4904468 Canine coronavirus vaccine_ Michael Gill, Stephen May assigned to Norden Laboratories Inc

《【病毒外文文獻】1990 4904468 Canine coronavirus vaccine_ Michael Gill, Stephen May assigned to Norden Laboratories Inc》由會員分享，可在線閱讀，更多相關(guān)《【病毒外文文獻】1990 4904468 Canine coronavirus vaccine_ Michael Gill, Stephen May assigned to Norden Laboratories Inc（2頁珍藏版）》請在裝配圖網(wǎng)上搜索。

New Patents xiii 4902616 PROCESS FOR THE PREPARATION OF CAPSULAR POLYSACCHARIDES OF STAPHYLOCOCCI THE POLYSACCHARIDES OBTAINED USES OF THESE POLYSACCHARIDES AND STRAINS FOR CARRYING OUT OF THE PROCESS Jean Michel Fournier Anne Bouvet Alain Boutonnier Paris France assigned to Institut Pasteur The subject of the invention is a process for the preparation of capsular polysaccharides charac teristic of Staphylococcus aureus comprising the use of coagulase negative strains of staphylococci for the preparation of these poly saccharides The capsular polysaccharides ob tained can be used for the preparation of vaccines against Staphylococcus aureus and dia gnostic agents There are disclosed compounds of the formula See Patent for Chemical Structure wherein X is CH or N Y is CHRI NR2 O or S RI is lower alkenyl lower alkynyl or unsubstituted or sub stituted phenyl naphthyl pyridyl pyrazinyl pyrimidinyl quinolyl quinazolinyl or quinox alinyl wherein the substituents are selected from halo lower alkyl lower alkoxy carboxy lower alkoxycarbonyl lower alkyl sulfonyl nitro cyano trifluoromethyl hydroxy mercapto and lower alkylthio and R2 is hydrogen lower alkyl lower alkenyl lower alkynyl or unsubstituted or substituted phenyl naphthyl pyridyl pyrazinyl pyrimidinyl quinolyl quinazolinyl or quinox alinyl wherein the substituents are selected from halo lower alkyl lower alkoxy carboxy lower alkoxycarbonyi lower alkylsulfonyl nitro cyano trifluoromethyl hydroxy mercapto and lower alkylthio with the proviso that when R2 is substituted phenyl the substituent is other than carboxy or lower alkoxycarbonyl which by vir tue of their ability to inhibit interleukin 1 are of use as antiinflammatory agents and in treatment of disease states involving enzymatic tissue destruction and there is also disclosed a method of using such compounds in the treatment of immunoinflammatory inflammatory prolifera tive and enzymatic tissue destruction conditions 4902618 PRODUCTION OF HYBRIDOMA ANTIBODIES FOR INTERFERON Kurt F Berg Gentofte Denmark assigned to Wadley Technologies lnc A hybridoma continuous cell line capable of producing monoclonal antibodies specific for all species of human interferon alpha is disclosed A method for producing hybridomas and mono clonal antibodies with the required specificity is also disclosed Methods of use of the disclosed compositions for purifying human interferon alpha screening blood in blood banks and for producing specific polyclonal antibodies are claimed and detailed 4904391 METHOD AND APPARATUS FOR REMOVAL OF CELLS FROM BONE MARROW Richard B Freeman An improved system for removing cells from bone marrow wherein the cells are bound by monoclonal antibodies conjugated to magnetic particles the system comprising a chamber pro vided with inlets and outlets for flowing through the chamber a liquid sample containing the bone marrow and magnetic conjugated antibodies bound to the cells and a magnetic field source as sociated with the chamber wherein the improve ment comprises a non uniform magnetic field in an ascending gradient from the inlet to the out let 4902685 2 AMINO 3 CYANO BICYCLIC PYRIDINES PYRAZINES AS INHIBITORS OF INTERLEUKIN 1 49O4468 CANINE CORONAVIRUS VACCINE Jerauld Skotnicki assigned to American Home Michael Gill Stephen May assigned to Norden Products Corporation Laboratories Inc xiv New Patents A vaccine for protecting canine animals from disease caused by infection with canine corona virus CCV which comprises an effective amount of the cell associated CCV peplomer protein A polyvalent vaccine comprising an ef fective amount of cell associated CCV peplomer protein and an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed 4904481 lymphocyte The medium may be a human body fluid or a culture medium A particular embodi ment of the present method involves a method for determining the presence of a AIDS virus in a person The method comprises combining a sample of a body fluid from the person with a monoclonal antibody that binds to an antigen produced as a result of the infection and detec ting the binding of the monoclonal antibody to the antigen The presence of the binding in dicates the presence of a AIDS virus infection Also disclosed are novel monoclonal antibodies noval compositions of matter and novel dia gnostic kits METHOD OF CONFERRING IMMUNO TOLERANCE TO A SPECIFIC ANTIGEN C Garrison Fathman assigned to The Board of Trustess of Leland Stanford University A method of selectively suppressing the immune system and conferring immunotolerance against a specific antigen by interferring with the L3T4 differentiation antigens on helper T cells is described Simultaneous administration of a bi nding moiety specific for the L3T4 equivalent in the subject species and a specific antigen or ad ministration of the antigen subsequent to the binding moiety for L3T4 equivalent within the time required for T cell recovery results in a diminished ability of the subject to respond immunologically to the antigen whether or not the subject has been exposed previously to the antigen 4904581 METHOD OF DETECTING AIDS VIRUS INFECTION Denis R Burger Andrew S Goldstein assigned to Epitope Inc A method is disclosed for detecting the presence of HTLV III infected cells in a medium The method comprises contacting the medium with monoclonal antibodies against an antigen pro duced as a result of the infection and detecting the binding of the antibodies to the antigen The antigen may be a gene product of the HTLV III virus or may be bound to such gene product On the other hand the antigen may not be a viral gene product but may be produced as a result of the infection and may further be bound to a 4904596 HYBRIDOMA ANTIBODY FH6 DEFINING A HUMAN CANCER ASSOCIATED DIFUCOGANGLIOSIDE Sen itiroh Hakomori assigned to Fred Hut chinson Cancer Research Center A hybridoma cell line ATCC No HB 8873 secreting a monoclonal IgM antibody FH6 directed to a fucoganglioside 6B which ac cumulates in human colonic adenocarcinoma but is absent in normal colonic mucosa The structure of the 6B ganglioside to which the anti body FH6 is directed is as follows See Patent for Chemical Structure See Patent for Tabular Pre sentation The hybridoma secreting the antibody FH6 was selected by reactivity of the FH6 anti body with the 6B ganglioside VI3NeuAcV3III3Fuc2nLc6 and lack of reac tivity with other glycolipids including glycolipids having closely related structures such as sialosyllactoneo tetraosylceramide IV3NeuAcnLc4 sialosyllactofucopen ta osy III ceramide IV3NeuAcllI3FucnLc4 sialosyllacto fucopentaosy I I ceramide sialosyl Lea glycolipid IV3NeuAclII4FucLc4 and 6C fucoganglioside sialosyl 2 right arrow6 fucoganglioside VI6NeuAcllI3FucnLc6 The antibody FH6 is highly reactive with a large variety of human cancer cells including colonic lung and breast cancer but does not react with most normal adult eels except notably granulocytes The antibody FH6 is of practical value in diagnostic tests and in monitoring and implementing various cancer treatments